Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.74 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.74 |
| ▸ | CA2 | P00918 | 1/20 | 0.74 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22398321 | 0.87 | CA12 (0.84) | CA12CA14CA2CA1CA7 | |
| SCHEMBL4442641 | 0.80 | CA12 (0.73) | CA12CA14CA2CA1CA7 | |
| SCHEMBL13966219 | 0.80 | CA12 (0.67) | CA12CA14CA2CA1CA7 | |
| SCHEMBL12959650 | 0.80 | GAA (0.46) | CA12CA14CA2CYP1A2GAA | |
| SCHEMBL8066895 | 0.78 | CA1 (0.68) | CA12CA14CA2CA1CA7 | |
| SCHEMBL1936376 | 0.78 | ALDH1A1 (0.52) | CA12CA14CA2CA1CYP1A2 | |
| SCHEMBL3295077 | 0.77 | CA12 (0.44) | CA12CA14CA2GAAMGAM | |
| SCHEMBL20646495 | 0.77 | CA12 (0.63) | CA12CA14CA2CA1CA7 | |
| SCHEMBL22404346 | 0.75 | CA12 (0.56) | CA12CA14CA2CA1CA7 | |
| SCHEMBL16472070 | 0.75 | CA12 (0.65) | CA12CA14CA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810104-B | Method for synthesizing indoleamine 2, 3-dioxygenase inhibitors | 因赛特控股公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-3744715-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | Incyte Holdings Corporation (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3744715-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | Incyte Holdings Corporation (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3066085-B1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3066085-B1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2020-05-13 | — | — | EP | disclosed |
| CN-109810104-A | Method for synthesis of indole amine 2,3- dioxygenase inhibitor | 因赛特控股公司 | 2019-05-28 | — | — | CN | disclosed |
| US-10280157-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280157-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2019-05-07 | — | — | US | disclosed |
| CN-105899498-B | Method for synthesizing indoleamine 2, 3-dioxygenase inhibitors | 因赛特控股公司 | 2019-01-25 | — | — | CN | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-20080045706-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045531-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-02-21 | — | — | US | disclosed |
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045706-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CA12 2354/4885CA14 3053/4885CA2 860/4885 |
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | CA12 4553/4885CA14 4756/4885CA2 3205/4885 |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | CA12 1747/4885CA14 2343/4885CA2 857/4885 |
| US-20080045531-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CA12 2354/4885CA14 3053/4885CA2 860/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | CA12 4553/4885CA14 4756/4885CA2 3205/4885 |
| US-10280157-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | IDO1, INMT, IDO2 | CA12 3758/4885CA14 3477/4885CA2 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.